Kathmandu School of Law Review

P-ISSN : 2091-2110, E-ISSN : 2773-8159, DOI : 10.46985, Publisher : Kathmandu School of Law, Nepal
Annual flagship journal of Kathmandu School of Law, Nepal

Volume 8, Issue 1, April 2020
Articles

Exclusivity in Times of a Public Necessity: Balance of Interests in South Asia’s Compulsory Licensing Regime

PDF
  • Neha Dhavalikar
    ,
  • Ashok Pandey
Neha Dhavalikar
B.A. LL.B 4th Year Student at Indian Law Society Law College, Pune
Ashok Pandey
B.A. LL.B 4th Year Student at Indian Law Society Law College, Pune
DOI: https://doi.org/10.46985/kslr.v8i1.2125

Published 2021-07-09

How to Cite

Dhavalikar, N. ., & Pandey , A. . (2021). Exclusivity in Times of a Public Necessity: Balance of Interests in South Asia’s Compulsory Licensing Regime. Kathmandu School of Law Review, 8(1), 1–20. https://doi.org/10.46985/kslr.v8i1.2125
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

The catastrophic impact of the COVID-19 pandemic on every facet of human life has made the requirement of a pharmaceutical breakthrough in the form of a vaccine more urgent than ever. The urgency has led to a hundred plus researches being underway, with tremendous amounts of capital and intellect invested. The vaccine being an invention, invites patent regulations and the rights of the patent holder associated with the invention. However, given the urgency of the situation, countries need to ensure hassle free access to the vaccine. Here, Compulsory Licensing regulations would play an important role. Beginning with a historical background of Compulsory Licensing under TRIPS, the authors analyse its subsequent amendment keeping in view the right of countries to give primacy to public health over intellectual property protection. The authors then highlight the diverse legislative positions of Compulsory Licensing in South Asia through the lens of the TRIPS position. The authors also comment upon Patent Pools, a comparatively new concept in the area of public health which is gaining spotlight. Further emphasis has been laid on keeping administrative impediments minimal with regards to the working of the intellectual property. This is important since firstly, the majority of the attempts underway are a collaborative innovation involving multiple stakeholders and secondly, multiple patent applications could be filed for different parts of a single invention leading to complexities while licensing. Finally, suggestions have been given as to how the patent regulations could be worked so as to maintain a balance between the rights of the patent holder and public health.

PDF

Downloads

Download data is not yet available.

References

  1. ‘Vaccines: The basics’, Centers for Disease Control and Prevention, available at https://www.cdc.gov/vaccines/vpd/vpd-vac-basics.html, accessed on 2 August 2020.
  2. Douglas Broom, ‘5 charts that tell the story of vaccines today’, World Economic Forum, 2 June 2020, available at https://www.weforum.org/agenda/2020/06/vaccine-development-barriers-coronavirus/, accessed on 2 August 2020.
  3. Ibid.
  4. Broom (n 2).
  5. ‘30 groups in India working on COVID-19 vaccine, development may cost $2-3 billion if done in a year’, DNA, 28 May 2020,available at https://www.dnaindia.com/health/report-30-groups-in-india-working-on-covid-19-vaccine-development-may-cost-2-3-billion-if-done-in-a-year-2826266, accessed on 2 August 2020.
  6. Divya Shekhar, ‘The race to make a Covid-19 vaccine in India’, Forbes India, 21 May 2020, available at https://www.forbesindia.com/article/coronavirus/the-race-to-make-a-covid19-vaccine-in-india/59547/1, accessed on 2 August 2020.
  7. Ibid.
  8. Broom (n 2).
  9. James Simon and others, ‘Managing severe acute respiratory syndrome (SARS) intellectual property rights: the possible role of patent pooling’, Bulletin of the World Health Organization p. 707, volume 83:9, 2005, p. 708, available at https://www.who.int/bulletin/volumes/83/9/707.pdf?ua=1, accessed on 24 July 2020.
  10. Sarah Neway, ‘WHO Patent Pool for potential COVID-19 products is nonsense’, The Telegraph, 29 May2020, available athttps://www.telegraph.co.uk/global-health/science-and-disease/patent-pool-potential-covid19-products-nonsense-pharma-leaders/, accessed on 13 July 2020.
  11. Adrian Johns, Piracy: The Intellectual Property Wars from Gutenberg to Gates, University of Chicago Press Books 2010, Chicago, 1st edition, 2010, p. 274.
  12. Paris Convention for the Protection of Industrial Property, 26 April 1970, 828 U.N.T.S. 305, Paris, 20 March 1883, art. 5.
  13. ‘Overview: the TRIPS Agreement’, World Trade Organization, available at https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm#standards, accessed on 10 July 2020.
  14. Agreement on Trade-Related Aspects of Intellectual Property Rights, 1 January 1995, 1869 U.N.T.S. 299, Uruguay, 15 April 1994, art. 31.
  15. Ibid, art. 31(h).
  16. Implementation of Paragraph 6 of The Doha Declaration on The TRIPS Agreement and Public Health, 1 September 2003, WTO General Council Meeting of 30 August 2003, Geneva, para. 4.
  17. ‘Members OK amendment to make health flexibility permanent’, World Trade Organisation, 06/12/2005, available at https://www.wto.org/english/news_e/pres05_e/pr426_e.htm, accessed on 10 July 2020.
  18. ‘Amendment to the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS)’, World Trade Organisation, 23 January 2017, available at, https://www.wto.org/english/tratop_e/trips_e/tripsfacsheet_e.htm, accessed on 10 July 2020.
  19. Neway (n 10).
  20. ‘AIDS and essential medicines and Compulsory Licensing’, Access Campaign, 26/02/1999, available at https://msfaccess.org/aids-and-essential-medicines-and-compulsory-licensing, accessed on 11 July 2020.
  21. Bob Aroture, ‘10 examples of the use of Compulsory Licenses for AIDS-Related Pharmaceuticals in Africa’, Nigerian Law Intellectual Property Watch Inc., 02 August 2013, available athttps://nlipw.com/10examples-of-the-use-of-compulsory-licenses-in-africa-2/, accessed on 12 July 2020.
  22. Bianca Nogrady, ‘US buys 3 months’ worth of Remdesivir stocks’, Medical Republic, 1 July 2020, available athttp://medicalrepublic.com.au/liveblog1july2020/30950, accessed on 13 July 2020.
  23. Neway (n 10).
  24. Bayer Corporation v. Natco Pharma Ltd., Intellectual Property Appellate Board, Chennai, 2013, SCC OnLine IPAB 25, p. 25.
  25. Reji K. Joseph, ‘US tries to thwart TRIPS flexibilities in the midst of a pandemic’, Livemint, 1 May2020, available athttps://www.livemint.com/opinion/online-views/us-tries-to-thwart-trips-flexibilities-in-themidstof-a-pandemic-11588320583933.html, accessed on 14 July 2020.
  26. Kate Kelland, ‘Faltering AIDS battle risks 10-year setback from COVID-19, UN warns’, Reuters, 6 July 2020, available at https://www.aol.com/article/news/2020/07/06/faltering-aids-battle-risks-10-year-set-backfrom-covid-19-un-warns/24547777/, accessed on 14 July 2020.
  27. ‘Global HIV and AIDS- 2020 Factsheet’, UNAIDS, available at https://www.unaids.org/en/resources/ fact-sheet, accessed on 14 July 2020.
  28. ‘Goal 3: Ensure healthy lives and promote well-being for all at all ages’, United Nations Department of Economic and social affairs-Sustainable Development, available at https://sdgs.un.org/goals/goal3, accessed on 1 August 2020.
  29. ‘Draft Landscape of COVID-19 candidate vaccines’, World Health Organisation, 31 July 2020, available athttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines, accessed on 2 August 2020.
  30. Carlos Correa, Trade Related Aspects of Intellectual Property Rights: A Commentary on the TRIPS Agreement, Oxford University Press, UK, 1st edition,2007, p. 314.
  31. Richard Rozeck & Renee Rainey, ‘Broad-based Compulsory Licensing of pharmaceutical technologies – Unsound public policy’, The Journal of World Intellectual Property p. 463, volume 4:4, 2005, p. 471.
  32. F. Michael Scherer, ‘Comment’. in Anderson and Gallini (eds), Competition Policy and Intellectual Property Rights in the Knowledge- based Economy, University of Calgary Press, Calgary, 1st edition, 1998, p. 163.
  33. Ibid.
  34. Correa (n 30), p. 316.
  35. Agreement on Trade-Related Aspects of Intellectual Property Rights, 1 January 1995, 1869 U.N.T.S. 299, Uruguay, 15 April 1994, art. 8.
  36. Correa (n 30), p. 318.
  37. Correa (n 30), p. 320.
  38. Council Discussion on Access to Medicines: Developing country group’s paper, IP/C/W/296, para. 28.
  39. Abraar Karan, ‘Opinion: It's Time To End The Colonial Mindset In Global Health’, Goats and Soda, 30 December 2019, available at https://www.npr.org/sections/goatsandsoda/2019/12/30/784392315/opinion-its-time-to-end-the-colonial-mindset-in-global-health, accessed on 24 January 2021.
  40. K. M. Gopakumar, ‘Twenty years of TRIPS Agreement and access to medicine: a development perspective’, Indian Journal of International Law, p. 367, volume55, 2015.
  41. Rajeshwar Chigullapalli and Feroz Zaheer, ‘Asia- The Emerging R&D hub’, PLG Group, available athttp://plg-group.com/wp-content/uploads/2014/03/Asia-ermering-pharma-RD-Hub-R-Chigullapalli-F.Saheer.pdf, accessed on 24 January 2021.
  42. Carlos M. Correa, ‘Implication of the Doha Declaration on the TRIPS Agreement and Public Health (2002) Essential Drugs and Medicine Policy’, World Trade Organisation, available at https://www.who.int/ medicines/areas/policy/WHO_EDM_PAR_2002.3.pdf, accessed on 3 August 2020.
  43. Correa (n 30), p. 321.
  44. Implementation of Paragraph 6 of The Doha Declaration on The TRIPS Agreement and Public Health, WT/L/540, p. 1, para. 5.
  45. TRIPS Agreement, art. 31(g).
  46. Correa (n 30), p. 322.
  47. James Love, ‘Remuneration guidelines for non-voluntary use of a patent on medical technologies’, World Health Organization, 2005, Washington D.C., paras. 19-28.
  48. Ibid.
  49. TRIPS Agreement, art. 31(i).
  50. Correa (n 30), p. 324.
  51. Implementation of Paragraph 6 of The Doha Declaration on The TRIPS Agreement and Public Health, WT/L/540, p. 4, para. 6.
  52. Correa (n 30), pp. 328-229.
  53. Ibid, p. 330.
  54. Ibid, p. 336.
  55. Ibid, p. 338.
  56. ‘WTO members agree to extend Drug Patent exemptions for poorest members’ World Trade Organisation, 6 November 2015, available at https://www.wto.org/english/news_e/news15_e/trip_06nov15_e.htm, accessed on 27 July 2020.
  57. Daniel Collopy & Yeo Moon Teng, ‘Myanmar’s New Patent Law’ Spurson and Ferguson Intellectual Property, 13 February 2020, available at https://www.spruson.com/patents/myanmars-new-patent-law/, accessed on 27 July 2020.
  58. Paris Convention for the Protection of Industrial Property, 26 April 1970,828 U.N.T.S. 305, Paris, 20 March 1883, art. 5(4).
  59. Patents and Designs Act, 1911, Bangladesh, s. 25.
  60. World Bank, ‘GDP Per Capita-South Asia’, available at https://data.worldbank.org/indicator/NY.GDP. PCAP.KD?locations=8S, accessed on 28 July 2020.
  61. Esteban Burrone, ‘Patent Pooling in Public Health’ in Margaret Chon, Pedro Roffe and Ahmed AbdelLatif (eds), The Cambridge Handbook of Public-Private Partnerships, Intellectual Property Governance, and Sustainable Development, Cambridge University Press, 2018, UK, 1st edition, 2018, p. 93.
  62. Burrone et. al., ‘Patent Pooling to increase access to essential medicines’ 97(8) Bulletin of the World Health Organization 2019, available at https://www.who.int/bulletin/volumes/97/8/18-229179.pdf, accessed on 3 August 2020.
  63. ‘WHO submission to the United Nations Secretary General high-level panel on access to medicines’ World Health Organization, 7 March 2016, available at https://static1.squarespace.com/static/562094dee4b0d00c1a3ef761/t/56e746279f7266a586c2b893/1457997352055/WHO_HLP_ Submission_7Mar2016.pdf, accessed 29 July 2020.
  64. ‘The Medicines Patent Pool and Untaid respond to access efforts for COVID-19 treatments and technologies’ Medicines Patent Pool, 31 March 2020, available at https://medicinespatentpool.org/news-publication-spost/the-medicines-patent-pool-and-unitaid-respond-to-access-efforts-for-covid-19-treatments-and-technologies/, accessed on 29 July 2020.
  65. ‘WHO and Costa Rica Preview Technology Pooling Initiative to Ensure Access to COVID-19 Healthcare Products for All’ World Health Organisation, 15 May 2020, available at https://www.who.int/news-room/ detail/15-05-2020-who-and-costa-rica-preview-technology-pooling-initiative-to-ensure-access-to-covid19-health-products-for-all, accessed on 29 July 2020.
  66. William Worley, ‘WHO and Costa Rica launch COVID-19 Technology Access Pool’, Devex, 29 May 2020), available at https://www.devex.com/news/who-and-costa-rica-launch-covid-19-technology-accesspool97368, accessed 30 July 2020.
  67. Ibid.
  68. ‘Public Statement for Collaboration on COVID-19 Vaccine Development’ World Health Organisation, 13 April 2020, available at https://www.who.int/news-room/detail/13-04-2020-public-statement-for-collaboration-on-covid-19-vaccine-development, accessed on 1 August 2020.
  69. ‘Patents’, World Intellectual Property Organisation, available at https://www.wipo.int/patents/en/, accessed on 24 January 2021.
  70. Title 35 of United States Code, 1952, United States of America, s. 262.
  71. Patent Law of the People's Republic of China, 1984, China, s. 2.
  72. Indian Patents Act, 1970, India, s. 50.
  73. Indian Patents Act, 1970, India, s. 51.
  74. ‘Merits & Demerits of Multiple Inventions in A Single Patent Application’ Intepat, 27 April 2020, available at https://www.intepat.com/blog/patent/multiple-inventions-in-a-single-patent-application-meritsdemerits/, accessed on 1 August 2020.
  75. Directive 2019/790 on copyright and related rights in the Digital Single Market, 2019, European Parliament and Council, p.1.
  76. Eddie Powell & Tim Wright, ‘The Open COVID Pledge’ Fladgate, 30 April 2020, available at https://www.fladgate.com/2020/04/the-open-covid-pledge/, accessed on 3 August 2020.